Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13-C-Pyruvate MRSI Reproducibility in Prostate Cancer
NCT03581500Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [1-13C]pyruvate in prostate adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Reproducibility of the key performance indicator at 3 years. Planned start Feb 2019; status: withdrawn.
02
Drugs
[1-13C]pyruvate
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT03581500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581500.